San Antonio, Tex—Scientists have achieved success using neuroprotectant drugs to limit stroke injury in animal models, but transferring these outcomes to humans has been disappointing.
Dozens of clinical trials have failed to show efficacy for a variety of neuroprotectants, but researchers are not giving up. They theorize that the lack of positive results in humans may be due to giving improper dosages, studying too broad a population in clinical trials, and allowing delays in administering the drugs.
Mitka M. News About Neuroprotectants for the Treatment of Stroke. JAMA. 2002;287(10):1253-1254. doi:10.1001/jama.287.10.1253-JMN0313-2-1